KRAS and colorectal carcinoma: Only mutant KRAS, mutant BRAF, MSI and the Oncotype DX® Colon Cancer Assay are currently used in clinical practice for determining whether to treat metastatic CRC patients with cetuximab or panitumumab, for the evaluation of Lynch syndrome and to inform treatment planning in stage II and -III colon cancer patients.